| Project/Area Number |
18K07278
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Hyogo Medical University |
|---|
Principal Investigator |
Eguchi Ryoji 兵庫医科大学, 医学部, 助教 (00461088)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
若林 一郎 兵庫医科大学, 医学部, 教授 (70220829)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 血管新生 / 非小細胞肺癌 / 無血清培養 / 3次元培養 / VEGF / HDGF / FGF-2 / 血管内皮増殖因子 / 肝細胞癌由来増殖因子 / 繊維芽細胞増殖因子-2 / 塩基性繊維芽細胞増殖因子 |
|---|
| Outline of Final Research Achievements |
In the present study, I aimed at identification of angiogenic factors derived from non-small cell lung cancer (NSCLC). EBC-1, a NSCLC cell line, was incubated in serum-free culture, in which eleven candidates were found by mass spectrometry. Among the eleven proteins, vascular endothelial growth factor (VEGF) and hepatoma-derived growth factor (HDGF) regulated angiogenesis induced by EBC-1 cells. However, VEGF and HDGF were not involved in angiogenesis induced by another NSCLC cell line, Lu99. By gene microarray in EBC-1 and Lu99 cells, three candidates were expressed in only Lu99 cells. Among the three genes, fibroblast growth factor-2 (FGF-2) regulated angiogenesis induced by Lu99 cells. These results suggest that HDGF enhances VEGF-dependent angiogenesis and FGF-2 is a VEGF-independent angiogenic factor in human NSCLC cells.
|
| Academic Significance and Societal Importance of the Research Achievements |
本邦で承認されている非小細胞肺癌の抗血管新生療法は、奏効率、無増悪生存期間、全生存期間の延長が報告されているが、それでもその平均生存期間は1年半と短いことから、他の血管新生因子の関与が考えられる。これまでにも非小細胞肺癌のVEGFとは異なる血管新生因子としてHDGFやFGF-2は報告されていたが、本研究の成果はそれらの報告を裏付ける研究結果となった。HDGFやFGF-2をターゲットとした抗血管新生療法の開発が期待される。
|
